These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 32949960)

  • 61. Recent Advances of DprE1 Inhibitors against
    Amado PSM; Woodley C; Cristiano MLS; O'Neill PM
    ACS Omega; 2022 Nov; 7(45):40659-40681. PubMed ID: 36406587
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Assay development and inhibition of the
    Batt SM; Toth S; Rodriguez B; Abrahams KA; Veerapen N; Chiodarelli G; Cox LR; Moynihan PJ; Lelievre J; Fütterer K; Besra GS
    Microbiology (Reading); 2023 Jan; 169(1):. PubMed ID: 36748627
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Design, synthesis and antitubercular assessment of 1, 2, 3-triazole incorporated thiazolylcarboxylate derivatives.
    Bakale RD; Sulakhe SM; Kasare SL; Sathe BP; Rathod SS; Choudhari PB; Madhu Rekha E; Sriram D; Haval KP
    Bioorg Med Chem Lett; 2024 Jan; 97():129551. PubMed ID: 37979730
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Antituberculars which target decaprenylphosphoryl-β-D-ribofuranose 2'-oxidase DprE1: state of art.
    Buroni S; Pasca MR; de Jesus Lopes Ribeiro AL; Degiacomi G; Molteni E; Riccardi G
    Appl Microbiol Biotechnol; 2012 May; 94(4):907-16. PubMed ID: 22526781
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Benzothiazinones are suicide inhibitors of mycobacterial decaprenylphosphoryl-β-D-ribofuranose 2'-oxidase DprE1.
    Trefzer C; Škovierová H; Buroni S; Bobovská A; Nenci S; Molteni E; Pojer F; Pasca MR; Makarov V; Cole ST; Riccardi G; Mikušová K; Johnsson K
    J Am Chem Soc; 2012 Jan; 134(2):912-5. PubMed ID: 22188377
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Identification of Potential Antituberculosis Drugs Through Docking and Virtual Screening.
    Anand R
    Interdiscip Sci; 2018 Jun; 10(2):419-429. PubMed ID: 27147082
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Structural basis of inhibition of Mycobacterium tuberculosis DprE1 by benzothiazinone inhibitors.
    Batt SM; Jabeen T; Bhowruth V; Quill L; Lund PA; Eggeling L; Alderwick LJ; Fütterer K; Besra GS
    Proc Natl Acad Sci U S A; 2012 Jul; 109(28):11354-9. PubMed ID: 22733761
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Identification and Profiling of Hydantoins-A Novel Class of Potent Antimycobacterial DprE1 Inhibitors.
    Rogacki MK; Pitta E; Balabon O; Huss S; Lopez-Roman EM; Argyrou A; Blanco-Ruano D; Cacho M; Vande Velde CML; Augustyns K; Ballell L; Barros D; Bates RH; Cunningham F; Van der Veken P
    J Med Chem; 2018 Dec; 61(24):11221-11249. PubMed ID: 30500189
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Novel Antitubercular Agents: Design, Synthesis, Molecular Dynamic and Biological Studies of Pyrazole - 1,2,4-Triazole Conjugates.
    Ajin KA; Arun Kumar S; Singh M; Akshatha HS; Bhagyalalitha M; Pujar KG; Sumana MN; Chandrashekar VM; Bidye D; Pujar GV
    Chem Biodivers; 2023 Nov; 20(11):e202300971. PubMed ID: 37882429
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Docking- and pharmacophore-based virtual screening for the identification of novel Mycobacterium tuberculosis protein tyrosine phosphatase B (MptpB) inhibitor with a thiobarbiturate scaffold.
    Zhang D; Lin Y; Chen X; Zhao W; Chen D; Gao M; Wang Q; Wang B; Huang H; Lu Y; Lu Y
    Bioorg Chem; 2019 Apr; 85():229-239. PubMed ID: 30641319
    [TBL] [Abstract][Full Text] [Related]  

  • 71. High content screening identifies decaprenyl-phosphoribose 2' epimerase as a target for intracellular antimycobacterial inhibitors.
    Christophe T; Jackson M; Jeon HK; Fenistein D; Contreras-Dominguez M; Kim J; Genovesio A; Carralot JP; Ewann F; Kim EH; Lee SY; Kang S; Seo MJ; Park EJ; Skovierová H; Pham H; Riccardi G; Nam JY; Marsollier L; Kempf M; Joly-Guillou ML; Oh T; Shin WK; No Z; Nehrbass U; Brosch R; Cole ST; Brodin P
    PLoS Pathog; 2009 Oct; 5(10):e1000645. PubMed ID: 19876393
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The DprE1 enzyme, one of the most vulnerable targets of Mycobacterium tuberculosis.
    Riccardi G; Pasca MR; Chiarelli LR; Manina G; Mattevi A; Binda C
    Appl Microbiol Biotechnol; 2013 Oct; 97(20):8841-8. PubMed ID: 24037308
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Inhibitor binding studies of
    Mallavarapu BD; Abdullah M; Saxena S; Guruprasad L
    J Biomol Struct Dyn; 2019 Sep; 37(14):3751-3763. PubMed ID: 30239262
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Quinolone analogues of benzothiazinone: Synthesis, antitubercular structure-activity relationship and ADME profiling.
    Dube PS; Legoabe LJ; Jordaan A; Sigauke L; Warner DF; Beteck RM
    Eur J Med Chem; 2023 Oct; 258():115539. PubMed ID: 37321107
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Leads for antitubercular compounds from kinase inhibitor library screens.
    Magnet S; Hartkoorn RC; Székely R; Pató J; Triccas JA; Schneider P; Szántai-Kis C; Orfi L; Chambon M; Banfi D; Bueno M; Turcatti G; Kéri G; Cole ST
    Tuberculosis (Edinb); 2010 Nov; 90(6):354-60. PubMed ID: 20934382
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Identification of a novel inhibitor of isocitrate lyase as a potent antitubercular agent against both active and non-replicating Mycobacterium tuberculosis.
    Liu Y; Zhou S; Deng Q; Li X; Meng J; Guan Y; Li C; Xiao C
    Tuberculosis (Edinb); 2016 Mar; 97():38-46. PubMed ID: 26980494
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Identification of Antimycobacterial Agent Using In Silico Virtual Screening, ADME Prediction, Docking, and Molecular Dynamics Simulations Approach.
    Tripathy S; Sahu SK; Azam MA; Jupudi S; Gupta VK; Sharma S
    Curr Comput Aided Drug Des; 2021; 17(6):806-816. PubMed ID: 32748754
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Structure-based screening and molecular dynamics simulations offer novel natural compounds as potential inhibitors of Mycobacterium tuberculosis isocitrate lyase.
    Shukla R; Shukla H; Sonkar A; Pandey T; Tripathi T
    J Biomol Struct Dyn; 2018 Jun; 36(8):2045-2057. PubMed ID: 28605994
    [TBL] [Abstract][Full Text] [Related]  

  • 79. 3D QSAR, Docking, Molecular Dynamics Simulations and MM-GBSA studies of Extended Side Chain of the Antitubercular Drug (6S) 2-Nitro-6- {[4-(trifluoromethoxy) benzyl] oxy}-6,7-dihydro-5H-imidazo[2,1-b] [1,3] oxazine.
    Chaudhari HK; Pahelkar A
    Infect Disord Drug Targets; 2019; 19(2):145-166. PubMed ID: 30324898
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Synthesis and Structural Elucidation of Novel Benzothiazole Derivatives as Anti-tubercular Agents: In-silico Screening for Possible Target Identification.
    Venugopala KN; Chandrashekharappa S; Pillay M; Bhandary S; Kandeel M; Mahomoodally FM; Morsy MA; Chopra D; Aldhubiab BE; Attimarad M; Alwassil OI; Harsha S; Mlisana K; Odhav B
    Med Chem; 2019; 15(3):311-326. PubMed ID: 29968540
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.